Since SPATA2 has been identified as a TNFR1 modulator required for TNF-induced inflammation and necroptosis [12, 14], some authors have attempted to study the expression of SPATA2 and TNFA in the tissues of 171 patients with low-grade serous ovarian cancer (LGSOC), high-grade serous ovarian cancer (HGSOC), endometrioid and clear cell ovarian cancer (OC) compared to 28 non-malignant control tissues [32]. The gene discussed is SPATA2; the disease is ovarian serous adenocarcinoma.